drugset / Trial / NCT07633119
A Phase Ⅲ Clinical Study of SNA02-48 Injection
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The primary objective of this clinical trial is to compare the efficacy and safety of SNA02-48 injection with Human Tetanus Immunoglobulin (HTIG) for tetanus prophylaxis.
Timeline
- Start
- 2026-06-28
- Primary completion
- 2027-03-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Human tetanus immunoglobulin | Protein / enzyme biologic | — | Intramuscular |
| Subject | SNA02-48 | Monoclonal antibody | — | Intramuscular |